Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Journal: Leukemia research
Published: March 12, 2020
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Journal: American journal of medical genetics. Part A
Published: July 26, 2018
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Journal: Blood cancer journal
Published: September 27, 2017
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Journal: Leukemia research
Published: July 17, 2017
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Journal: The oncologist
Published: May 23, 2016
Showing 1-6 of 6
Last Updated: 09/26/2026